PPARG and cardiac hypertrophy: Whether the cardiac hypertrophy caused by rosiglitazone occursthrough PPAR-γ independenteffects in cardiomyocytes, PPAR-γ in nonmyocyte cells, or blood volume expansion[33, 48], remains to be furtherdetermined.